← Back to Search

Verapamil and Citicoline for Stroke (SCAVINGER Trial)

Phase 1
Waitlist Available
Led By Justin Fraswer, MD
Research Sponsored by Justin Fraser
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 48 hours after treatment
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the safety and feasibility of super-selective intra-arterial administration of verapamil and citicoline immediately following successful endovascular thrombectomy as a potential neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke. This trial represents the first time that citicoline will be evaluated in human subjects as a superselectively administered neuroprotective agent administered in an acute time frame as an adjunct to intra-arterial thrombectomy. Furthermore, it will represent the first trial to evaluate combinational therapy for acute stroke neuroprotection.

Eligible Conditions
  • Stroke

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 48 hours after treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 48 hours after treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intracranial Hemorrhage
Secondary study objectives
Citicoline

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Verapamil and CiticolineExperimental Treatment1 Intervention
10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
Group II: PlaceboPlacebo Group1 Intervention
The control group will receive saline only.

Find a Location

Who is running the clinical trial?

Justin FraserLead Sponsor
4 Previous Clinical Trials
1,069 Total Patients Enrolled
3 Trials studying Stroke
1,059 Patients Enrolled for Stroke
Justin Fraswer, MDPrincipal InvestigatorUniversity of Kentucky
~0 spots leftby Nov 2025